目的:分析糖尿病护理领域研究的现状、热点及前沿。方法:运用CiteSpace可视化分析软件从Web of Science的核心合集数据库检索并下载2011年—2020年糖尿病护理领域研究的2125篇相关文献。结果:研究国家及机构主要集中于欧美等发达国家地...目的:分析糖尿病护理领域研究的现状、热点及前沿。方法:运用CiteSpace可视化分析软件从Web of Science的核心合集数据库检索并下载2011年—2020年糖尿病护理领域研究的2125篇相关文献。结果:研究国家及机构主要集中于欧美等发达国家地区,研究热点集中于糖尿病的管理、全球糖尿病患病率的预测、糖尿病病人发生心血管疾病的风险干预、青少年糖尿病病人方面;研究前沿主要围绕量表的开发与验证、糖尿病病人的体验等方面。结论:国际上对糖尿病护理领域研究的范围不断扩展和深入,关注国际研究热点及前沿对于国内开展相关研究以优化糖尿病护理具有重要价值和意义。展开更多
Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administr...Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administration(FDA).Odevixibat,maralixibat chloride and belzutifan approved in 2021 could be applied in the treatment of progressive familial intrahepatic cholestasis(PFIC),cholestatic pruritus and clear cell renal cell carcinoma(ccRCC),respectively.In 2022,abrocitinib,pyrukynd and voquezna were approved for the treatment of atopic dermatitis,pyruvate kinase deficiency(PKD)and acid-related disorders,respectively.Defencath for preventing bloodstream infections,sparsentan for treatment of proteinuria related to IgA nephropathy,and xacduro for treatment of hospital-acquired bacterial pneumonia(HABP)were approved in 2023.In this review,the synthesis and therapies of these sulfuryl group-involved drugs approved from 2021 to 2023 are discussed in details.展开更多
文摘目的:分析糖尿病护理领域研究的现状、热点及前沿。方法:运用CiteSpace可视化分析软件从Web of Science的核心合集数据库检索并下载2011年—2020年糖尿病护理领域研究的2125篇相关文献。结果:研究国家及机构主要集中于欧美等发达国家地区,研究热点集中于糖尿病的管理、全球糖尿病患病率的预测、糖尿病病人发生心血管疾病的风险干预、青少年糖尿病病人方面;研究前沿主要围绕量表的开发与验证、糖尿病病人的体验等方面。结论:国际上对糖尿病护理领域研究的范围不断扩展和深入,关注国际研究热点及前沿对于国内开展相关研究以优化糖尿病护理具有重要价值和意义。
文摘Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administration(FDA).Odevixibat,maralixibat chloride and belzutifan approved in 2021 could be applied in the treatment of progressive familial intrahepatic cholestasis(PFIC),cholestatic pruritus and clear cell renal cell carcinoma(ccRCC),respectively.In 2022,abrocitinib,pyrukynd and voquezna were approved for the treatment of atopic dermatitis,pyruvate kinase deficiency(PKD)and acid-related disorders,respectively.Defencath for preventing bloodstream infections,sparsentan for treatment of proteinuria related to IgA nephropathy,and xacduro for treatment of hospital-acquired bacterial pneumonia(HABP)were approved in 2023.In this review,the synthesis and therapies of these sulfuryl group-involved drugs approved from 2021 to 2023 are discussed in details.
